Vale SA
VALE
D.R. Horton
DHI
Taylor Morrison Home
TMHC
4
Petroleo Brasileiro SA Petrobras
PBR
5
Ecopetrol
EC
US Stock MarketDetailed Quotes
VNDA Vanda Pharmaceuticals
- 4.990
- -0.090-1.77%
Close Mar 18 16:00 ET
- 4.990
- 0.0000.00%
Post 19:34 ET
291.00MMarket Cap-15.12P/E (TTM)
5.020High4.870Low454.06KVolume5.010Open5.080Pre Close2.25MTurnover0.88%Turnover RatioLossP/E (Static)58.32MShares6.75052wk High0.54P/B257.67MFloat Cap3.85552wk Low--Dividend TTM51.64MShs Float33.440Historical High--Div YieldTTM2.95%Amplitude0.450Historical Low4.962Avg Price1Lot Size
About Vanda Pharmaceuticals Company
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Company Profile
SymbolVNDA
Company NameVanda Pharmaceuticals
Listing DateApr 12, 2006
Issue Price10.00
Founded2002
CEODr. Mihael Hristos Polymeropoulos,M.D.
MarketNASDAQ
Employees368
Fiscal Year Ends12-31
Address2200 Pennsylvania Avenue Northwest,Suite 300 E
CityWashington
ProvinceDistrict of Columbia
CountryUnited States of America
Zip Code20037
Phone1-202-734-3400
Websitehttp://www.vandapharma.com
Company Executives
- Name
- Position
- Salary
- Dr. Mihael Hristos Polymeropoulos,M.D.
- Chairman of the Board, President and Chief Executive Officer
- 3.72M
- Joakim Wijkstrom
- Senior Vice President and Chief Marketing Officer
- 1.36M
- Kevin Moran
- Senior Vice President, Principal Accounting Officer, Chief Financial Officer and Treasurer
- 1.32M
- Timothy Williams
- Senior Vice President, General Counsel and Secretary
- 1.40M
- Gunther Birznieks
- Senior Vice President, Business Development
- 1.37M
- Phaedra S. Chrousos
- Independent Director
- 300.00K
- Dr. Stephen Ray Mitchell, M.B.A.,M.D.
- Independent Director
- 282.50K
- Anne Sempowski Ward
- Independent Director
- 302.50K
- Richard W. Dugan
- Lead Independent Director
- 332.50K
- Dr. Tage Honore, D.Sc.,PhD
- Independent Director
- 602.43K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call